Abiraterone and Increased Survival in Metastatic Prostate Cancer
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index; 17 of the 40 sources its claims cite were checked for support.
Abstract
BACKGROUND: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS: We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS: After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the preplanned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo-prednisone group. CONCLUSIONS: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 7 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A unique molecular alteration described in castration-resistant prostate cancer is the up-regulation of androgen biosynthesis enzymes, leading to an increase in intratumoral androgen concentrations, which can exceed the levels measured in the blood.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [7] matched to “Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance” (2004) source
- Partly supportedcites [8] matched to “Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer” (2006) sourceExperimental — accuracy not yet measured
The Abstract and Discussion (page numbers unavailable) report increased expression of androgen-metabolism genes in androgen-independent prostate cancer and propose enhanced intracellular conversion of adrenal androgens as a mechanism for substantial tissue androgen levels. The paper does not state that intratumoral androgen concentrations exceed blood levels; its tissue comparison is with normal or nonneoplastic prostate. (LLM, conf=0.88)
- Partly supportedcites [9] matched to “Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth” (2008) sourceExperimental — accuracy not yet measured
The Results report up-regulated transcripts for androgen-biosynthesis enzymes in castration-resistant metastases and say tumor testosterone concentrations exceeded equivalent concentrations in the patients’ serum. But the Discussion says the processes sustaining intratumoral androgens have yet to be determined and proposes enzyme modulation as a possible mechanism; it does not establish that the up-regulation caused the higher concentrations. No page number is available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Treatment with abiraterone acetate did not appear to increase the risk of metabolic changes or symptoms associated with chronic androgen deprivation.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Could not verifycites [42] matched to “Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer” (2010) sourceExperimental — accuracy not yet measured
The Methods passage describes GnRH agonists, orchiectomy, and oral antiandrogens, but does not identify abiraterone acetate as a treatment studied. The Results and Discussion address diabetes and cardiovascular outcomes for those treatments, not metabolic changes or symptoms during abiraterone treatment. Searches for “abiraterone acetate” and the claimed metabolic changes and symptoms found no passage addressing that specific claim. (LLM, conf=0.77)
- Could not verifycites [43] matched to “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology” (2010) sourceExperimental — accuracy not yet measured
The 'Adverse Effects of ADT' section describes metabolic changes associated with androgen-deprivation therapy generally, but does not assess abiraterone acetate. Searches for 'abiraterone acetate' and 'symptoms associated with chronic androgen deprivation' found no passage addressing whether abiraterone increases those risks. (LLM, conf=0.76)
- Not checked yetcites [44] matched to “Management of Complications of Prostate Cancer Treatment” (2008) source
- Not checked yetcites [45] matched to “Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer” (2004) source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These results show that continued androgen-receptor signaling contributes to disease progression”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Not checked yetcites [2] matched to “Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis” (2005) source
- Supportedcites [10] matched to “Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?” (2009) source
The Abstract of the Attard et al. (2009) Cancer Cell preview states that 'clinical data from abiraterone acetate and MDV-3100 confirm continued androgen receptor (AR) addiction in a significant proportion of castration-resistant prostate cancers,' and the Main Text adds that 'the growth of the majority of cancer cells in many patients with cancers recurring after castration remains dependent on the AR signaling axis,' with nuclear AR expression persisting in metastases and AR transcriptional activity described as 'required for prostate cancer progression' (Hormone-Driven Oncogenesis). The conclusion reiterates that a significant proportion of CRPC finds AR signaling 'a hard habit to break.' This covers the claim's substance — persistent AR signaling contributing to progression in metastatic CRPC — though the source phrases it as addiction/persistence in a significant proportion rather than in all patients. (LLM, conf=0.88)
- Not checked yetcites [31] matched to “Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling” (2011) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In phase 1–2 trials, treatment with abiraterone acetate, either as a single agent or in combination with low-dose glucocorticoids such as prednisone, resulted in significant antitumor activity among both patients with progressing castration-resistant prostate cancer who had not received chemotherapy and those who had received chemotherapy.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
The Abstract Patients and Methods (p.1) and Introduction state this phase I/II trial enrolled castrate, chemotherapy-naive CRPC patients only, and the PATIENTS AND METHODS > Patients section explicitly excludes 'Patients who had previously received cytotoxic chemotherapy or a radiopharmaceutical'; the antitumor activity figures (≥50% PSA decline in 67% of 42, RECIST partial responses in 9/24, Abstract Results) therefore apply solely to the chemotherapy-naive population. The low-dose glucocorticoid component is supported in that the study prospectively added dexamethasone 0.5 mg/d at progression and reversed resistance in 33% of patients (Abstract Results; Discussion). What this source does not support is the post-chemotherapy arm of the claim: the Discussion mentions only that a phase III study of abiraterone plus prednisone in docetaxel-treated patients 'is now being evaluated,' with no results reported here. (LLM, conf=0.85)
- Supportedcites [16] matched to “Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids” (2010) source
In the body of this correspondence (section 'Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids'), the authors open by summarising the three multicenter phase I/II studies of abiraterone acetate in CRPC (chemotherapy-naive Ryan et al, and the post-docetaxel Reid et al and Danila et al studies listed in their References) and state that their prechemotherapy data 'confirmed the significant antitumor activity of abiraterone acetate' (radiologic regression, PSA and circulating tumour cell decreases), that the combination with low-dose corticosteroids (dexamethasone/prednisone) gave 'durable secondary tumor responses... in 25% of patients', and close by affirming 'the significant and durable antitumor activity and the satisfactory safety profile of abiraterone acetate at 1,000 mg daily'. Low-dose prednisone is explicitly named. This source is correspondence reporting/summarising those trials rather than a primary trial report, but it states every element attributed to it here. (LLM, conf=0.82)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy is a single phase I trial, and it confirms significant antitumor activity (PSA declines ≥30%/≥50% in 66%/57% of 21 patients, RECIST partial responses in 5 of 8) in chemotherapy-naive CRPC (Antitumor Activity section), with low-dose dexamethasone 0.5 mg/d added at progression reinducing sensitivity in 4 of 15 patients (Reversal of Resistance section). However, the post-chemotherapy arm and the phase II results are not reported here: the Discussion (B2 C1 C2) states only that these findings 'have led to the phase II evaluation... in both chemotherapy-naïve and docetaxel-treated patients... data from this evaluation will be reported soon,' and the Patients section explicitly excluded men previously treated with chemotherapy. Prednisone is not the glucocorticoid used in this paper (dexamethasone was), so the 'phase 1-2 trials... both chemotherapy-naive and post-chemotherapy' scope is not carried by this source. (LLM, conf=0.78)
- Supportedcites [18] matched to “Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer” (2010) source
Our copy covers every element of the summary sentence. The Abstract and Results describe this phase II trial of abiraterone acetate 1,000 mg daily with low-dose prednisone 5 mg twice daily in 58 men with progressive metastatic CRPC after docetaxel failure, reporting significant antitumor activity (confirmed ≥ 50% PSA decline in 36%, partial responses in 4/22 RECIST-evaluable patients, ECOG improvement in 28%). The Introduction states that 'Significant antitumor effects were seen in patients with progressive CRPC who had not received prior chemotherapy' (citing the phase I trial, Attard 2008, and the phase II chemo-naive AA-plus-prednisone study, Ryan 2009) and that 'In a separate trial, we showed significant antitumor effects of abiraterone acetate (AA) monotherapy in this patient group' (post-docetaxel, Reid/Danila), i.e. activity with AA alone as well as with low-dose steroid, in both chemotherapy-naive and post-chemotherapy settings. The Discussion likewise frames this as 'the second trial showing the activity of AA in patients ... who have progressed on chemotherapy.' (LLM, conf=0.85)
- Partly supportedcites [19] matched to “Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate” (2010) sourceExperimental — accuracy not yet measured
Our copy directly supports the trial/patient-population part: the Conclusion (p. 1) and DISCUSSION (p. 5) state that abiraterone acetate 1,000 mg had significant antitumor activity in post-docetaxel CRPC (≥50% PSA declines in 51%, with radiologic, symptomatic and CTC support), and the INTRODUCTION (p. 2) plus DISCUSSION (p. 6) report the authors' own phase I and phase II pre-docetaxel (chemotherapy-naïve) studies as showing abiraterone 'well tolerated and active'. What our copy does not support is the efficacy attribution to a glucocorticoid combination: low-dose glucocorticoids (and eplerenone) appear only as management of mineralocorticoid-excess toxicities (Treatment and Procedures, p. 3; Safety, p. 5; DISCUSSION, p. 6), the trial itself was single-agent abiraterone, and prednisone co-administration is mentioned only as the design of the subsequent phase III trial (DISCUSSION, p. 5), not as a phase 1-2 activity result. (LLM, conf=0.78)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) supports only part of the sentence: the DISCUSSION (p. 1) states 'Abiraterone acetate has significant activity in patients with CRPC, as evidenced by a PSA response rate of 58% in this phase I trial,' and RESULTS/Efficacy report confirmed ≥50% PSA declines in 55%-58% of men with chemotherapy-naïve progressive CRPC, including 47% of those with prior ketoconazole. However, this is a single-agent phase I dose-escalation trial only — 'Prior chemotherapy for prostate cancer was not allowed' (Major Eligibility Criteria), and the DISCUSSION states the exclusion of prior-chemotherapy patients was intentional, with 'ongoing studies...evaluating abiraterone in patients with both chemotherapy-refractory and chemotherapy-naïve CRPC,' so the post-chemotherapy activity attributed here is not from this paper. Glucocorticoids were also not part of the tested regimen: prednisone/corticosteroids were used reactively to manage mineralocorticoid toxicity, and the authors only 'suggest that a low dose of a corticosteroid, such as prednisone, be administered with abiraterone acetate in future studies'; the DISCUSSION notes 'the impact of concurrent prednisone on response proportion and durability...is not known.' (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile observed in the group of patients who received abiraterone acetate was similar to that observed in earlier clinical studies.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
Our copy details the safety profile of the 1,000-mg abiraterone acetate group in RESULTS > Safety Profile (secondary mineralocorticoid excess: hypokalemia 88%, hypertension 40%, fluid overload 31%, managed with eplerenone; grade 3 transaminase elevation in 2 patients; grade 1 headaches/joint aches) and calls it 'effective, well-tolerated' in the DISCUSSION, so the first half of the claim is grounded. However, no passage states that this profile was 'similar to that observed in earlier clinical studies'; the only cross-study safety remarks compare abiraterone with ketoconazole trials (grade >=3 toxicities in up to 30% of patients, all requiring hydrocortisone) and explicitly caution that 'it is difficult to make any comparisons.' The prior abiraterone phase I experience is referenced (ref 15) as having identified the 1,000-mg dose, not as a matched safety comparison. The comparative/similarity element is therefore unsupported by our copy. (LLM, conf=0.68)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy documents this trial's own safety profile (Safety and Tolerability: dose escalation to 2,000 mg achieved, no treatment-related grade 3 or 4 toxicities, hypertension/hypokalemia/edema controlled with eplerenone; DISCUSSION: toxicities predominantly due to secondary mineralocorticoid excess), and the INTRODUCTION notes that first-in-man studies reported abiraterone acetate was safe when given daily for 12 days to men with prostate cancer. However, no passage compares the two or states the profiles were similar; the only 'similar' statement in the paper is of hypertension incidence across dose levels within this study, and the DISCUSSION frames this as 'the first study to demonstrate that selective and continuous inhibition of CYP17 is safe', with the earlier clinical experience being short-course dosing in noncastrate men. The comparative element of the claim ('similar to that observed in earlier clinical studies') is therefore not supported by this source. (LLM, conf=0.65)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) describe their own safety findings as acceptable and consistent with expected CYP17 inhibition (DISCUSSION: 'The adverse event and steroid endocrine profiles were consistent with anticipated outcomes of selective CYP17 inhibition'; well tolerated through 1,000 mg/d with no MTD and no toxicity difference by prior ketoconazole exposure, DISCUSSION). However, the only external comparison our copy makes is to a CONCURRENT study, not to earlier clinical studies: RESULTS (Dose Escalation) states 'These findings paralleled a concurrent study with abiraterone acetate.' The claim's framing of similarity to 'earlier clinical studies' is therefore not supported by this source. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
23 more claims · 3 with their cited sources checked
Create a free account to see all 50 claims and to verify the 23 references still open.
- It may state two separate claims as one. 10
- The quote only partly states this claim. 3
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abiraterone acetate is an orally active prodrug of abiraterone, a potent P450c17 inhibitor (316) indicated for treatment of castration-resistant prostate cancer (317, 318).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [317]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [20]
In the citing paper
“Abiraterone is a potent CYP17A1 inhibitor that efficiently inhibits testosterone production120 and is used to treat prostate cancer.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [120]
In the citing paper
“Additionally, androgen biosynthesis from C21 precursors can be reduced by CYP17A1 inhibition with abiraterone as successfully applied for the treatment of CRPC (Attard et al., 2008, de Bono et al., 2011, James et al., 2017).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as de Bono et al., 2011
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 3×
“Bone pain 194 (25) 42 (5) 2 (<1) 110 (28) 25 (6) 4 (1)”
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241 · cited 1×
“Fluid retention and edema 241 (31) 16 (2) 2 (<1) 88 (22) 4 (1) 0”
Self-citationde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182 · cited 2×
“Nausea 233 (30) 12 (2) 1 (<1) 124 (32) 10 (3) 0”
Self-citationDevelopment of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Cited by
Items 401–500 of 1,010
The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis
Mei, W., Lin, X., Kapoor, A., Gu, Y. J., Zhao, K., & Tang, D. (2019) · Cancers · doi:10.3390/cancers11040434 · Cited by 117
“Docetaxel-based therapy was reported to extend the median OS of CRPC for approximately three months [11,12], as resistance rapidly develops.”
BackgroundInfluentialFred Saad, C., Efstathiou, E., Attard, G., Flaig, T. W., Franke, F. A., Goodman, O. B., Oudard, S. M., Steuber, T. P., Suzuki, H., Wu, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00402-2 · Cited by 111
Self-citationQu, F., Xie, W., Nakabayashi, M., Zhang, H., Jeong, S. H., Wang, X., Komura, K., Sweeney, C. J., Sartor, O. A., Lee, G. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1070 · Cited by 116
“Even though studies have shown that these drugs prolong overall survival (OS), a significant proportion of patients does not respond to these drugs or develops resistance shortly after the treatment (18-23).”
The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing Data
Green, A. K., Reeder-Hayes, K. E., Corty, R. W., Basch, E., Milowsky, M. I., Dusetzina, S. B., Bennett, A. V., & Wood, W. A. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0431 · Cited by 123
Sternberg, C., Armstrong, A., Pili, R., Ng, S., Huddart, R., Agarwal, N., Khvorostenko, D., Lyulko, O., Brize, A., Vogelzang, N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9697 · Cited by 105
Self-citationGenetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
Lozano, R., Castro, E., Aragón, I. M., Cendón, Y., Cattrini, C., Lopez-Casas, P. P., & Olmos, D. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01114-x · Cited by 119
The Role of Genetic Markers in the Management of Prostate Cancer
Choudhury, A. D., Eeles, R. A., Freedland, S. J., Isaacs, W. B., Pomerantz, M. M., Schalken, J. A., Tammela, T. L. J., & Visakorpi, T. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.054 · Cited by 116
“The androgen receptor (AR) signaling pathway remains critical in CRPC, as demonstrated by clinical responses to novel agents decreasing circulating androgens to below castration levels (abiraterone) [69] and more potent antagonists of the AR (eg, MDV3100) [70].”
BackgroundChi, K. N., Spratlin, J. L., Kollmannsberger, C., North, S. A., Pankras, C., Gonzalez, M., Bernard, A., Stieltjes, H., Peng, L., Jiao, J. J., et al. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.564 · Cited by 112
Self-citationYap, T. A., & Workman, P. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134532 · Cited by 106
Decker, K. F., Zheng, D., He, Y., Bowman, T. A., Edwards, J. R., & Li, J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks888 · Cited by 116
Recent trends in the management of advanced prostate cancer
Ritch, C. R., & Cookson, M. S. (2018) · F1000Research · doi:10.12688/f1000research.15382.1 · Cited by 111
Neuwirt, H., Bouchal, J., Kharaishvili, G., Ploner, C., Jöhrer, K., Pitterl, F., Weber, A., Klocker, H., & Eder, I. E. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-019-0505-5 · Cited by 115
Qiao, Y., Choi, J. E., Tien, J. C.-Y., Simko, S. A., Rajendiran, T. M., Vo, J. N., Delekta, A. D., Wang, L., Xiao, L., Hodge, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00237-1 · Cited by 114
Liedtke, A. J., Adeniji, A. O., Chen, M., Byrns, M. C., Jin, Y., Christianson, D. W., Marnett, L. J., & Penning, T. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017656 · Cited by 101
Halabi, S., Armstrong, A. J., Sartor, O. A., Bono, J. S. D., Kaplan, E. B., Lin, C., Solomon, N. C., & Small, E. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3201 · Cited by 113
Wallis, C. J. D., Klaassen, Z. W. A., Bhindi, B., Goldberg, H., Chandrasekar, T., Farrell, A. M., Boorjian, S. A., Kulkarni, G. S., Karnes, R. J., & Satkunasivam, R. (2017) · European Urology · doi:10.1016/j.eururo.2017.10.002 · Cited by 114
“Similarly, abiraterone acetate, an inhibitor of cytochrome P-450c17, which is critical for androgen biosynthesis [8,9], demonstrated improved OS in the CRPC setting, both predocetaxel [10,11] and postdocetaxel treatment [12,13].”
BackgroundSerum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study
Jamnagerwalla, J., Howard, L. E., Allott, E. H., Vidal, A. C., Moreira, D. M., Castro‐Santamaria, R., Andriole, G. L., Freeman, M. R., & Freedland, S. J. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-017-0030-9 · Cited by 106
“Prostate cancer is unique in its dependence on androgens for growth [19].”
BackgroundLeibowitz‐Amit, R., Templeton, A. J., Omlin, A. G., Pezaro, C. J., Atenafu, E. G., Keizman, D., Vera-Badillo, F., Seah, J.-A., Attard, G., Knox, J. J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt581 · Cited by 113
“Several new agents were shown to prolong survival of patients with metastatic castration-resistant prostate cancer (mCRPC) after chemotherapy, including cabazitaxel [1], abiraterone [2], enzalutamide [3] and radium-223 [4].”
InfluentialTreating Prostate Cancer by Antibody–Drug Conjugates
Rosellini, M., Santoni, M., Mollica, V., Rizzo, A., Cimadamore, A., Scarpelli, M., Storti, N., Battelli, N., Montironi, R., & Massari, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041551 · Cited by 114
“Abiraterone acetate is a selective inhibitor of CYP17A1, and it has proven able to gain OS and PFS improvement in patients previously treated with docetaxel in the phase III COU-AA-301 trial, compared with prednisone alone [27].”
MethodGoodman, O. B., Flaig, T. W., Molina, A., Mulders, P., Fizazi, K. S., Suttmann, H., Li, J., Kheoh, T. S., Bono, J. S. D., & Scher, H. I. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.41 · Cited by 110
Self-citationLiu, C., Armstrong, C. M., Zhu, Y., Lou, W., & Gao, A. C. (2016) · Oncotarget · doi:10.18632/oncotarget.8493 · Cited by 108
Hager, S., Ackermann, C. J., Joerger, M., Gillessen, S., & Omlin, A. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw156 · Cited by 108
“Nevertheless, it seems interesting that the objective RRs in some of the trials are not so different from the objective RR that have been shown in the phase III trials of approved substances [3, 4, 6, 8, 99].”
BackgroundMetronomic chemotherapy for cancer treatment: a decade of clinical studies
Romiti, A., Cox, M. C., Sarcina, I., Rocco, R. D., D’Antonio, C., Barucca, V., & Marchetti, P. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2125-x · Cited by 114
“001) were even improved by abiraterone compared with placebo [132].”
Breast cancer: Current and future endocrine therapies
Palmieri, C., Patten, D. K., Januszewski, A. P., Zucchini, G., & Howell, S. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.001 · Cited by 112
Current therapeutic options in metastatic castration-resistant prostate cancer
Ingrosso, G., Detti, B., Scartoni, D., Lancia, A., Giacomelli, I., Baki, M., Carta, G. A., Livi, L., & Santoni, R. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.10.001 · Cited by 111
Robinson, J. L. L., Hickey, T. E., Warren, A. Y., Vowler, S. L., Carroll, T., Lamb, A. D., Papoutsoglou, N., Neal, D. E., Tilley, W. D., & Carroll, J. S. (2014) · Oncogene · doi:10.1038/onc.2013.508 · Cited by 101
“Enzalutamide) has produced improved outcomes for patients with CRPC, but they are not universally effective and responses are not durable (3, 4).”
BackgroundJin, R., Yamashita, H., Yu, X., Wang, J., Franco, O. E., Wang, Y., Hayward, S. W., & Matusik, R. J. (2014) · Oncogene · doi:10.1038/onc.2014.302 · Cited by 110
The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer
Choi, S. Y. C., Xue, H., Wu, R. C., Fazli, L., Lin, D., Collins, C. C., Gleave, M. E., Gout, P. W., & Wang, Y. Z. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1624 · Cited by 100
“Although the efficacy of mCRPC treatment has recently been improved by using more powerful chemotherapeutics targeting the androgen receptor (AR) signaling axis, such as enzalutamide (3) and abiraterone (4), the overall survival of patients has only marginally increased (5–7).”
BackgroundLipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade
Flaig, T. W., Salzmann-Sullivan, M., Su, L.-J., Zhang, Z., Joshi, M., Gijón, M. A., Kim, J., Arcaroli, J. J., Van Bokhoven, A., Lucia, M. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17359 · Cited by 99
“com/oncotarget Although new Highly-Effective Androgen Therapy (HEAT) such as the androgen receptor inhibitor Enzalutamide [6] and the androgen biosynthesis inhibitor Abiraterone acetate [7] have been shown to provide a survival advantage in mCRPC, virtually all patients acquire secondary resistance [8].”
BackgroundSelf-citationLSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression
Liang, Y., Ahmed, M., Guo, H., Soares, F., Hua, J. T., Gao, S., Lu, C., Poon, C., Han, W., Langstein, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0496 · Cited by 101
“The recent clinical success of abiraterone (a CYP17A1 inhibitor that further suppresses androgen synthesis) and enzalutamide (a second-generation AR antagonist) has confirmed that AR signaling is a key driver of tumor progression in CRPC (3-5).”
BackgroundHan, W., Gao, S., Barrett, D. A., Ahmed, M., Han, D. G., Macoska, J. A., He, H. H., & Cai, C. (2017) · Oncogene · doi:10.1038/onc.2017.385 · Cited by 108
“The recurrence of the cancer is largely due to residual androgens that contribute to persistent AR activity and, therefore, many patients with CRPC respond to therapies that further suppress androgen synthesis or to more potent AR antagonists 3–5 .”
Advances in the management of castration resistant prostate cancer
Ritch, C. R., & Cookson, M. S. (2016) · BMJ · doi:10.1136/bmj.i4405 · Cited by 109
Trump, D. L., & Aragon‐Ching, J. B. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_14_18 · Cited by 111
A review of prostate cancer treatment impact on the CNS and cognitive function
Ryan, C. J., Wefel, J. S., & Morgans, A. K. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0195-5 · Cited by 113
Self-citationShore, N. D., Laliberté, F., Ionescu-Ittu, R., Yang, L., Mahendran, M., Lejeune, D., Yu, L. H., Burgents, J., Duh, M. S., & Ghate, S. R. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01823-6 · Cited by 97
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer
Devos, G., Devlies, W., Meerleer, G. D., Baldewijns, M. M. L. L., Gevaert, T., Moris, L., Milonas, D., Poppel, H. V., Berghen, C., Everaerts, W., et al. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00514-9 · Cited by 117
Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency
Auchus, R. J., Buschur, E. O., Chang, A. Y., Hammer, G. D., Ramm, C., Madrigal, D., Wang, G., Gonzalez, M., Xu, X. S., Smit, J. W., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1258 · Cited by 97
Substrate-modulated Cytochrome P450 17A1 and Cytochrome b5 Interactions Revealed by NMR
Estrada, D. F., Laurence, J. S., & Scott, E. E. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.468926 · Cited by 100
Li, R., Evaul, K., Sharma, K. K., Chang, K.-H., Yoshimoto, J., Liu, J., Auchus, R. J., & Sharifi, N. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0908 · Cited by 97
“resistance occurs, and analysis of urinary androgen metabolites shows that CYP17A1 inhibition is incomplete, suggesting the possibility of sustained steroidogenesis (11, 13).”
BackgroundSeitz, A. K., Thoene, S., Bietenbeck, A., Nawroth, R., Tauber, R., Thalgott, M. K., Schmid, S. C., Secci, R., Retz, M. M., Gschwend, J. E., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.07.024 · Cited by 99
The Microwell-mesh: A high-throughput 3D prostate cancer spheroid and drug-testing platform
Mosaad, E. M. O., Chambers, K., Futrega, K., Clements, J. A., & Doran, M. R. (2018) · Scientific Reports · doi:10.1038/s41598-017-18050-1 · Cited by 107
Neuroendocrine and Aggressive-Variant Prostate Cancer
Spetsieris, N., Boukovala, M. A., Patsakis, G., Alafis, I., & Efstathiou, E. (2020) · Cancers · doi:10.3390/cancers12123792 · Cited by 100
Self-citationTriggiani, L., Mazzola, R., Magrini, S. M., Ingrosso, G., Borghetti, P., Trippa, F., Lancia, A., Detti, B., Francolini, G., Matrone, F., et al. (2019) · World Journal of Urology · doi:10.1007/s00345-019-02717-7 · Cited by 96
Giorgi, U. D., Caroli, P., Burgio, S. L., Menna, C., Conteduca, V., Bianchi, E., Fabbri, F., Carretta, E., Amadori, D., Paganelli, G., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2558 · Cited by 99
“Consequently, changes in radiological images have been advocated as important markers of disease response and progression to abiraterone [4, 5].”
BackgroundVenkitaraman, R., Lorente, D., Murthy, V., Thomas, K., Parker, L., Ahiabor, R., Dearnaley, D. P., Huddart, R. A., Bono, J. S. D., & Parker, C. C. (2014) · European Urology · doi:10.1016/j.eururo.2014.10.004 · Cited by 98
“In these trials, the PSA response rate to prednisolone has ranged from 16% to 24%, and the median time to PSA progression has ranged from2mo to 6mo [6–10].”
BackgroundMethodInfluentialToren, P., Kim, S., Pham, S., Mangalji, A., Adomat, H. H., Guns, E. S. T., Zoubeidi, A., Moore, W., & Gleave, M. E. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0521 · Cited by 96
“More recently, abiraterone acetate (AA) in combination with prednisone has demonstrated improved overall survival (OS) in both pre- and postchemotherapy patients with CRPC in phase III trials (2, 4).”
BackgroundAndrogen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein
Gao, S., Gao, Y., He, H. H., Han, D. G., Han, W., Avery, A., Macoska, J. A., Liu, X., Chen, S., Ma, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.064 · Cited by 101
“Residual androgens contribute to persistent AR activity in these relapsed tumors, and many patients with CRPC will respond to therapies that further suppress androgen synthesis or to new AR antagonists (de Bono et al., 2011; Scher et al., 2012).”
BackgroundDevelopment of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
Wang, X., Qiao, Y., Asangani, I. A., Ateeq, B., Poliakov, A., Cieslik, M. P., Pitchiaya, S., Chakravarthi, B. V. S. K., Cao, X., Jing, X., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.017 · Cited by 101
“Although a variety of next-generation compounds targeting androgen biosynthesis (de Bono et al., 2011) or androgen receptor (AR) activity (Tran et al., 2009) have shown efficacy in castration-resistant prostate cancer, the tumors invariably develop adaptive mechanisms.”
BackgroundMazziotti, G., Formenti, A. M., Frara, S., Roca, E., Mortini, P., Berruti, A., & Giustina, A. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0154 · Cited by 96
Recommandations en onco-urologie 2013 du CCAFU : Cancer de la prostate
Salomon, L., Bastide, C., Beuzeboc, P., Cormier, L., Fromont, G., Hennequin, C., Mongiat-Artus, P., Peyromaure, M., Ploussard, G., Renard‐Penna, R., et al. (2013) · The French Journal of Urology · doi:10.1016/s1166-7087(13)70048-4 · Cited by 113
Abiraterone acetate in the treatment of prostate cancer
Thakur, A., Roy, A., Ghosh, A., Chhabra, M., & Banerjee, S. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.067 · Cited by 112
Lorente, D., Olmos, D., Mateo, J., Dolling, D. I., Bianchini, D., Seed, G., Flohr, P., Crespo, M., Figueiredo, I., Miranda, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy172 · Cited by 101
“We report an unplanned post hoc analysis of the COU-AA-301 and IMMC-38 trials, both of which have been published previously [12, 14].”
MethodSelf-citationLee, G. T., Nagaya, N., Desantis, J., Madura, K., Sabaawy, H. E., Kim, W.-J., Vaz, R. J., Cruciani, G., & Kim, I. Y. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0417 · Cited by 91
“Yet, castrationresistant prostate cancer (CRPC) eventually emerges with a median survival time of 18–24 months (4–6).”
BackgroundInfluentialManagement of cancer treatment-induced bone loss
Coleman, R. E., Rathbone, E. J., & Brown, J. E. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.36 · Cited by 102
Armstrong, C. M., & Gao, A. C. (2015) · Europe PMC (PubMed Central) · Cited by 117
Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
de Leeuw, R., Berman-Booty, L. D., Schiewer, M. J., Ciment, S. J., Den, R. B., Dicker, A. P., Kelly, W. K., Trabulsi, E. J., Lallas, C. D., Gomella, L. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1358 · Cited by 101
“These include: i) the anti-androgen enzalutamide(6, 7), ii) the CYP17A1 inhibitor abiraterone acetate(8), iii) the alpha-emitting radiopharmaceutical radium-233(9), iv); the immunotherapeutic sipuleucel-T(10), and v) the new generation taxane cabazitaxel(11, 12).”
BackgroundFerraldeschi, R., Welti, J. C., Powers, M. V., Yuan, W., Smyth, T., Seed, G., Riisnaes, R., Hedayat, S., Wang, H., Crespo, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2186 · Cited by 103
“, enzalutamide) overcome several of the mechanisms underlying persistent AR transcriptional activity and have been shown to extend overall survival of patients with CRPC (2, 3).”
BackgroundInfluentialJazayeri, M. H., Amani, H., Pourfatollah, A. A., Avan, A., Ferns, G. A., & Pazoki–Toroudi, H. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.42 · Cited by 95
Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
Goyal, J., & Antonarakis, E. S. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.001 · Cited by 94
“inhibitor abiraterone is approved for docetaxel-pretreated men [11].”
BackgroundNunes, J. J., Pandey, S. K., Yadav, A., Goel, S., & Ateeq, B. (2017) · Neoplasia · doi:10.1016/j.neo.2017.02.002 · Cited by 97
“Recent studies demonstrated that AR-mediated signaling and downstream transcriptional activation are critical for the progression of CRPC despite castration [2], which led to the discovery of several novel therapies, namely, enzalutamide, a second-generation selective AR antagonist [5,6]; abiraterone acetate, a potent…”
Beer, T. M., Hotte, S. J., Fred Saad, C., Alekseev, B. Y., Matveev, V. B., Fléchon, A., Gravis, G., Joly, F., Chi, K. N., Malik, Z., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30605-8 · Cited by 105
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
Berruti, A., Pia, A., & Terzolo, M. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1107198 · Cited by 101
Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer
Ferraldeschi, R., Sharifi, N., Auchus, R. J., & Attard, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0931 · Cited by 93
Steroidogenic cytochrome P450 17A1 structure and function
Burris‐Hiday, S. D., & Scott, E. E. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111261 · Cited by 100
Burbach, B. J., O’Flanagan, S. D., Shao, Q., Young, K. M., Slaughter, J. R., Rollins, M. R., Street, T. J. L., Granger, V., Beura, L. K., Azarin, S. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24132-6 · Cited by 110
Vogelzang, N. J., Benowitz, S. I., Adams, S., Aghajanian, C. A., Chang, S. M., Dreyer, Z. E., Janne, P. A., Ko, A. H., Masters, G. A., Odenike, O. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1919 · Cited by 112
“The drug’s approval was based on results from a study of 1,195 patients with hormone-refractory prostate cancer in which patients received either abiraterone in combination with prednisone or a placebo with prednisone.(21) Patients who received the abirateroneprednisone combination had a median overall survival of 15…”
BackgroundA phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
Rathkopf, D. E., Picus, J., Hussain, A., Ellard, S. L., Chi, K. N., Nydam, T., Allen-Freda, E., Mishra, K., Porro, M. G., Scher, H. I., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2224-8 · Cited by 95
“Recent phase 3 data for enzalutamide and abiraterone confirm the central role of the AR and AR signaling in the progression of prostate cancer throughout the spectrum of the disease [29, 30].”
BackgroundSelf-citationPennati, M., Lopergolo, A., Profumo, V., Cesare, M. D., Sbarra, S., Valdagni, R., Zaffaroni, N., Gandellini, P., & Folini, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.009 · Cited by 98
“Although novel antiandrogen compounds, such as abiraterone acetate and enzalutamide, have been shown to palliate symptoms and prolong life [2,3], metastatic castration-resistant PCa remains incurable.”
BackgroundHodges, J. C., Lotan, Y., Boike, T. P., Benton, R., Barrier, A., & Timmerman, R. D. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2012.000548 · Cited by 97
Nuhn, P., Vaghasia, A. M., Goyal, J., Zhou, X. C., Carducci, M. A., Eisenberger, M. A., & Antonarakis, E. S. (2013) · British Journal of Urology · doi:10.1111/bju.12531 · Cited by 100
Bianchini, D., Omlin, A., Pezaro, C., Lorente, D., Ferraldeschi, R., Mukherji, D., Crespo, M., Figueiredo, I., Miranda, S., Riisnaes, R., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.619 · Cited by 91
Self-citationOmlin, A. G., Pezaro, C. J., Mukherji, D., Mulick, A. R., Sandhu, S. K., Bianchini, D., Olmos, D., Ferraldeschi, R., Maier, G., Thompson, E., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.12.029 · Cited by 95
“In the past 36 mo, five novel treatments have shown survival gains in phase 3 trials, including sipuleucel-T [6], abiraterone acetate [7,8], cabazitaxel [9], enzalutamide [10], and radium [11].”
BackgroundSelf-citationValidation and clinical utility of prostate cancer biomarkers
Scher, H. I., Morris, M. J., Larson, S. M., & Heller, G. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.30 · Cited by 96
Self-citationDu, Y., Weng, X., Wang, L., Liu, X., Zhu, H., Guo, J., Ning, J., & Xiao, C. (2017) · Oncotarget · doi:10.18632/oncotarget.21719 · Cited by 95
“Based on the fact that most tumor cells respond well to ADT therapy in the initial stage, the application of novel antiandrogens has prominently improved life expectancy and alleviated suffering in patients [22].”
BackgroundA noncanonical AR addiction drives enzalutamide resistance in prostate cancer
He, Y., Wei, T., Ye, Z., Orme, J. J., Lin, D., Sheng, H., Fazli, L., Karnes, R. J., Jiménez, R. E., Wang, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21860-7 · Cited by 102
Mitsiades, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4414 · Cited by 97
Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer
Smolle, M. A., Bauernhofer, T., Pummer, K., Călin, G. A., & Pichler, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020473 · Cited by 97
“As a cytochrome P450 17A1 (CYP17A1) inhibitor, abiraterone impedes the production of androgens in adrenal glands, cancer cells and other sources [15], whilst enzalutamide directly binds to the AR and blocks nuclear translocation and activation of downstream AR-related pathways [16].”
BackgroundParmar, M. K., Sydes, M. R., Cafferty, F. H., Choodari-Oskooei, B., Langley, R. E., Brown, L., Phillips, P. P., Spears, M. R., Rowley, S., Kaplan, R., et al. (2017) · Clinical Trials · doi:10.1177/1740774517725697 · Cited by 91
“In 2010, 5 years into STAMPEDE recruitment, the drug abiraterone was showing very promising results in patients with prostate cancer at more advanced stages than those entering STAMPEDE – that is, in patients with hormone refractory disease.(15) At this time, there were three realistic options: (a) choose to not test…”
BackgroundVelho, P. I., Fu, W., Wang, H., Mirkheshti, N., Qazi, F., Lima, F., Shaukat, F., Carducci, M. A., Denmeade, S. R., Paller, C. J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.05.032 · Cited by 100
“In this context, novel antiandrogens such as abiraterone [5,6] and enzalutamide [7,8] provide clinical and survival benefits, suggesting that mCRPC often remains addicted to androgens and AR signaling [2].”
BackgroundWang, J., Xu, W., Wang, B., Lin, G., Yu, W., Abudurexiti, M., Zhu, W., Liu, C., Qin, X., Dai, B., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.007 · Cited by 100
Regulation of cholesterol biosynthesis and cancer signaling
Gorin, A. A., Gabitova, L., & Astsaturov, I. A. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.011 · Cited by 105
Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents
Zhang, G., Liu, X., Li, J., Ledet, E., Alvarez, X., Qi, Y., Fu, X., Sartor, O., Dong, Y., & Zhang, H. (2015) · Oncotarget · doi:10.18632/oncotarget.4396 · Cited by 91
“Several new treatments, including the new taxane cabazitaxel [3], the CYP17A1 inhibitor abiraterone [4], and the potent antiandrogen enzalutamide [5], have received FDA approval as second-line treatments for metastatic CRPC in recent years.”
BackgroundYu, Z., Cai, C., Gao, S., Simon, N. I., Shen, H. C., & Balk, S. P. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0292 · Cited by 97
Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer
Hoffman-Censits, J. H., & Kelly, W. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2910 · Cited by 100
“7 Abiraterone/Zytiga (5) Postdocetaxel CRPC Placebo, Prednisone 0.”
BackgroundSternberg, C. N., Molina, A., North, S. A., Mainwaring, P. N., Fizazi, K. S., Hao, Y., Rothman, M. L., Gagnon, D. D., Kheoh, T. S., Haqq, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds585 · Cited by 96
“secondary outcomes have previously been described in detail [26].”
BackgroundInfluentialSelf-citationChi, K. N., Higano, C. S., Blumenstein, B. A., Ferrero, J.-M., Reeves, J. A., Feyerabend, S., Gravis, G., Merseburger, A. S., Stenzl, A., Bergman, A. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30168-7 · Cited by 101
Self-citationDesign of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer
Schneider, J. A., Craven, T. W., Kasper, A. C., Yun, C., Haugbro, M., Briggs, E. M., Svetlov, V., Nudler, E., Knaut, H., Bonneau, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06845-3 · Cited by 90
Barros-Silva, J. D., Linn, D. E., Steiner, I., Guo, G., Ali, A., Pakula, H., Ashton, G., Peset, I., Brown, M. D., Clarke, N. W., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.069 · Cited by 93
Danila, D. C., Szmulewitz, R. Z., Vaishampayan, U., Higano, C. S., Baron, A. D., Gilbert, H. N., Brunstein, F., Milojic-Blair, M., Wang, B., Kabbarah, O., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00646 · Cited by 90
Self-citationKolinsky, M. P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., Michalarea, V., Riisnaes, R., Crespo, M., Figueiredo, I., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.074 · Cited by 92
Self-citationAndrogens and prostate cancer; pathogenesis and deprivation therapy
Grossmann, M., Cheung, A. S., & Zajac, J. D. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.001 · Cited by 97
Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Endocrinology · doi:10.1210/en.2013-1466 · Cited by 110
The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer
Capper, C. P., Rae, J. M., & Auchus, R. J. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0259-0 · Cited by 89
“9 months in the abiraterone-treatment group compared to placebo [100].”
ResultCirculating Tumors Cells as Biomarkers: Progress Toward Biomarker Qualification
Danila, D. C., Pantel, K., Fleisher, M., & Scher, H. I. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e69ac · Cited by 100
“78).(133) For the biomarker portion of the study, the first question will be which specific posttherapy CTC biomarker criterion best associates with overall survival.”
BackgroundSelf-citationMcNeel, D. G., Eickhoff, J. C., Wargowski, E., Zahm, C. D., Staab, M. J., Straus, J., & Liu, G. (2018) · Oncotarget · doi:10.18632/oncotarget.25387 · Cited by 90
“These agents include docetaxel [2, 3], cabazitaxel [4], sipuleucel-T [5], abiraterone [6], enzalutamide [7], and radium-223 [8].”
BackgroundCellular rewiring in lethal prostate cancer: the architect of drug resistance
Carceles‐Cordon, M., Kelly, W. K., Gomella, L. G., Knudsen, K. E., Rodríguez-Bravo, V., & Domenech, J. M. D. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0298-8 · Cited by 101
Floc’h, N., Kinkade, C. W., Kobayashi, T., Aytés, À., Lefèbvre, C., Mitrofanova, A., Cardiff, R. D., Califano, A., Shen, M. M., & Abate-Shen, C. T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0283 · Cited by 91
“Recently, several agents that target androgen receptor and/or androgen synthesis, namely MDV3100 and Abiraterone, have been introduced into the clinic and have shown promising results (7, 8), although they are also not curative.”
Saeed, K., Rahkama, V., Eldfors, S., Bychkov, D., Mpindi, J. P., Yadav, B., Paavolainen, L., Aittokallio, T., Heckman, C., Wennerberg, K., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.04.019 · Cited by 89
Advancing Precision Medicine for Prostate Cancer Through Genomics
Roychowdhury, S., & Chinnaiyan, A. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3662 · Cited by 90
AR function in promoting metastatic prostate cancer
Augello, M. A., Den, R. B., & Knudsen, K. E. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9471-3 · Cited by 88
“In clinical trials, administration of abiraterone acetate significantly increased time to biochemical progression and radiographic progression-free survival, indicating that metastatic tumors are still reliant on AR signaling at this stage [34, 35, 38].”
Metadata
- Authors
- de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., & Scher, H. I.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Institut Gustave Roussy (FR)
- Cross Cancer Institute (CA)
- BC Cancer Agency (CA)
- University of Glasgow (GB)
- Institute of Cancer Research (GB)
- Velindre Cancer Centre (GB)
- University College London (GB)
- University of Colorado Cancer Center (US)
- University of Calgary (CA)
- University of California, San Francisco (US)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- Centre Léon Bérard (FR)
- Georgia Cancer Specialists (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Logothetis, Christopher J.
- Molina, Arturo
- Fizazi, Karim
- North, Scott
- Chi, Kim N.
- Jones, Robert J.
- Goodman, Oscar B.
- Staffurth, John N.
- Mainwaring, Paul
- Flaig, Thomas W.
- Hutson, Thomas E.
- Cheng, Tina
- Hainsworth, John D.
- Ryan, Charles J.
- Sternberg, Cora N.
- Ellard, Susan L.
- Fléchon, Aude
- Saleh, Mansoor
- Efstathiou, Eleni
- Bianchini, Diletta
- Loriot, Yohann
- Kheoh, Thian
- Haqq, Christopher M.
- Scher, Howard I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-26
- Volume
- 364
- Issue
- 21
- Pages
- 1995-2005
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3471149
- OpenAlex
- W2110534364
- Cited by
- 4,407
- References
- 54
- Citations by year
- 2026: 111 · 2025: 184 · 2024: 187 · 2023: 209 · 2022: 235 · 2021: 287 · 2020: 290 · 2019: 299 · 2018: 332 · 2017: 322 · 2016: 342 · 2015: 352 · 2014: 384 · 2013: 403 · 2012: 347
- FWCI
- 336.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Prostate Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- Les Laboratories Pierre Fabre
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research
- Astellas Pharma
- Genentech
- Foundation Medicine
- Medical Research Council
- National Cancer Institute (P50CA092629)
- Cilag
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- abiraterone, metastatic castration-resistant prostate cancer, androgen biosynthesis inhibition, overall survival, docetaxel, prednisone, prostate-specific antigen progression, progression-free survival, fluid retention, hypokalemia, hypertension
- MeSH terms
- Aged, Androgen Antagonists, Androgens, Androstenes, Androstenols, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Fatigue, Humans, Male, Middle Aged, Neoplasm Metastasis, Prednisone, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Survival Analysis, Treatment Outcome, Disease Progression, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.